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Objective  28 
This prospective study aimed to identify predictors of intention and subsequent attendance of 29 
flexible sigmoidoscopy screening using constructs derived from the Health Belief Model 30 
(HBM).  31 
Method 32 
4,330 people aged 54 and registered at one of 83 participating English General Practices  33 
were sent a pre-invitation questionnaire to assess socio-demographics, HBM variables  34 
including perceived benefits, barriers, seriousness, health motivation and external cues to 35 
action) as well a range of other constructs and personal characteristics known to relate to 36 
cancer screening.   37 
Results 38 
Of the 1,578 (36.4%) respondents, 1,555 (98.5%) answered the intention question: 52.9% 39 
stated ‘definitely yes’, 38.1% ‘probably yes’, 6.8% ‘probably not’ and 2.2% ‘definitely not’. 40 
Intentions were positively associated with a higher score on a scale of benefits (Odds Ratio 41 
[OR]: 4.62; 95% Confidence Intervals [CI]: 3.24-6.59) and health motivation, i.e. interest in 42 
other ways of preventing CRC (OR: 2.61; 95% CI: 1.62-4.22), while a higher score on 43 
perceived barriers (OR: 0.19; 95% CI: 0.12-0.31) and currently following recommended 44 
healthy lifestyle behaviours  (OR: 0.31; 95% CI: 0.16-0.59) were negatively associated. 45 
Attendance was verified for 922 (65.2%) intenders of whom 737 (79.9%) attended. 46 
Attendance was predicted by health motivation (OR: 1.75; 95% CI: 1.07-2.86), perceived 47 
benefits (OR: 1.82; 95% CI: 1.37-2.43), perceived barriers (OR: 0.47; 95% CI: 0.32-0.69), 48 
individual-level deprivation (OR: 0.26; 95% CI: 0.14-0.50) and having diabetes (OR: 0.48; 49 
95% CI: 0.25-0.94). 50 
Conclusion 51 
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This study supported the usefulness of the HBM in predicting cancer screening and was 52 
further enhanced by adding non-HBM variables such as individual socioeconomic 53 
deprivation and co-morbidities.   54 
 55 
Keywords: Cancer screening, flexible sigmoidoscopy, prospective questionnaire, intentions, 56 
attendance, Health Belief Model 57 
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In 2010, shortly after the publication of the 10-year follow-up data from the UK 64 
Flexible Sigmoidoscopy Screening Trial (UKFSST), the English government announced the 65 
introduction of flexible sigmoidoscopy screening as part of the existing NHS Bowel Cancer 66 
(Colorectal, CRC) Screening Programme (BCSP).  Following a pathfinder study in 2013 67 
(Bevan, Rubin, Sofianopoulo, Patnick & Rees, 2014), FS screening began to roll out, known 68 
as bowel scope screening (BSS). BSS is a one off FS screening test offered to adults aged 55 69 
who are registered with a primary care practitioner. No further bowel screening invitations 70 
are then offered until the age of 60 when they are then transferred into the guaiac faecal 71 
occult blood test part of the English BCSP (biennial invitations).   The swiftness with which 72 
FS was adopted reflected the dramatic potential public health benefits documented by Atkin 73 
and colleagues (Atkin et al., 2010), which has been further supported by more recent follow-74 
up data at 17 years (Atkin et al., 2017), as well as several other trials in other countries (e.g. 75 
US, Italy and Norway; Schoen et al., 2012; Segnan et al., 2011; Hoff, Grotmol, Skovlund & 76 
Bretthauer, 2009).  77 
Despite the fact that a once only FS screening test was found to halve CRC mortality 78 
and even reduce incidence by 32%, uptake has been low (Elmunzer et al., 2012). Within the 79 
first 14 months of the launch of BSS, uptake was 43% (McGregor et al., 2016a) thus making 80 
it the only organised NHS screening programme with less than 50% participation. By 81 
comparison recent uptake of cervical and breast screening in England has been reported to be 82 
around 70% (Public Health England 2017; Health and Social Care Information Centre, 2018). 83 
International data on uptake from trials of FS screening range between 32% in the 84 
Netherlands (Hol et al., 2010) to 65% in Norway (Hoff et al., 2009).  85 
Low uptake is further compounded by social inequalities including a socioeconomic 86 
gradient, with uptake ranging from 33-53% in the most and least deprived quintile in England 87 
respectively (McGregor et al., 2016a).   This finding was consistent with a socioeconomic 88 
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gradient which has consistently been observed in uptake of the FOB test (von Wagner et al. 89 
2011; Hirst et al., 2018).   There is also a substantial difference between areas with the 90 
highest level of ethnic diversity compared with less diverse areas (39 vs 41-47%), and a 91 
significant gender difference, with men being more likely to attend than women (45% vs. 92 
42%) (McGregor et al., 2016a).  93 
The significance of low uptake cannot be underestimated. Low uptake substantially 94 
reduces the potential public health benefit associated with the test (Geurts, Massat & Duffy, 95 
2015) and undermines its cost-effectiveness. It is therefore not surprising that there has been 96 
considerable effort at trying to understand factors associated with uptake of BSS (Hall et al., 97 
2016), and attempts to improve uptake (Kerrison et al., 2017; Kerrison et al., 2018; 98 
McGregor et al., 2016b). 99 
In terms of identifying determinants of uptake, the UKFSST identified several factors 100 
associated with intention to participate in FS screening, including the lack of immediate 101 
benefits, negative consequences of participation (e.g. anticipated pain and embarrassment) 102 
and cancer fear and fatalism (Power et al., 2008). Attendance in the UKFSST (which was 103 
limited to those with high intention) related more strongly to deprivation and stress (Power et 104 
al., 2008).  105 
In a recent review of the literature concerning factors associated with FS use as a 106 
screening test worldwide, factors most commonly found to have a positive association with 107 
uptake included low deprivation, male gender, and a family history of CRC, in addition to 108 
perceiving there to be low barriers and high benefits to doing the test (Kerrison et al., 2019).  109 
  110 
Furthermore, a qualitative study into BSS attendance has identified a perceived or 111 
actual lack of need to have the test, a lack of understanding of the benefits and harms of the 112 
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test, and more practical barriers such as the inability to make appointments (Hall et al., 2016). 113 
Yet current quantitative evidence is limited to studies of the UKFSST, while the only 114 
evidence from the BSS branch of the BSCP so far has been retrospective. For example, a 115 
recent survey identified overall pain and embarrassment to be the most commonly cited 116 
barriers to BSS participation among those who never responded to their invitation, and 117 
practical and appointment related reasons among those who had initially confirmed their 118 
appointment but subsequently failed to attend (von Wagner et al., 2018). While informative, 119 
retrospective research suffers from fundamental flaws, most prominently the possibility that 120 
reported barriers are post-hoc rationalisations rather than genuine reasons for non-attendance 121 
(Waller, Bartoszek, Marlow & Wardle, 2009). 122 
The present study used a large prospective survey with adults who were soon to be 123 
invited for screening. Of the relatively few studies that have explored psychological 124 
determinants from a theoretical perspective, most have used the Health Belief Model (HBM; 125 
Becker, Haefner and Maiman, 1977). The HBM is a behaviour change model which 126 
stipulates that engagement in health actions is influenced by people’s beliefs about the 127 
underlying illness or health problem (i.e. perceived susceptibility to, and severity of, the 128 
health threat), and behaviour specific cognitions and perceptions (i.e. perceived benefits and 129 
barriers).  In addition, the model was subsequently extended by adding non-core constructs 130 
including internal and external prompts which act as ‘cues to action’ and a person’s general 131 
motivation to look after their health was a later addition to the model (Becker, Haefner and 132 
Maiman, 1977; Abraham and Scheeran, 2015). Constructs such as perceived benefits and 133 
barriers have been found to explain a large proportion of variance in people’s motivation (or 134 
intention) to participate in cancer screening (Kiviniemi, Bennett, Zaiter & Marshall, 2011).  135 
As a result we used items to assess the components of the HBM in relation to colorectal 136 
cancer screening as the core of our survey. 137 
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In addition, the survey aimed to assess selected non HBM constructs which have been 138 
previously shown to influence behaviour, specifically fatalistic beliefs and knowledge of risk 139 
factors and external circumstances including both individual level and area level deprivation, 140 
and overall health, which have been identified as being directly associated with people’s 141 
ability to translate their intention into action (Power et al., 2008). Socioeconomic deprivation 142 
(i.e. the absence or lack of basic material benefits and resources considered necessary to 143 
function normally in society) has been repeatedly associated with health behaviours. In brief, 144 
being more deprived makes people more likely to engage in unhealthy behaviours while the 145 
opposite is the case for healthy behaviours (Pampel, Krueger, Denney, 2010). The latter has 146 
been clearly demonstrated in the case of colorectal cancer screening where (as described 147 
above) there is a strong link between socioeconomic status with screening attendance, 148 
including the NHS Bowel Scope Screening programme (von Wagner et al., 2011; McGregor 149 
et al., 2016).  The importance of documenting socioeconomic inequalities has also been well 150 
documented as socioeconomic differences in uptake will widen socioeconomic inequalities in 151 
colorectal cancer outcomes (Haggar & Boushey, 2009; von Wagner et al, 2011).   152 
We also explored the role of two specific chronic illnesses as there is emerging evidence of 153 
the complex role of chronic illness on cancer screening and symptomatic help seeking (Renzi, 154 
Kaushal, Hamilton ….Lyratzopoulos, in press).  While respondents with an inflammatory 155 
bowel disease such as Crohn’s disease were excluded from the study because they would 156 
have been ineligible for BSS screening, we were keen to ascertain whether a self-disclosed 157 
diagnosis of irritable bowel syndrome would affect BSS attendance.  In addition, we wanted 158 
to explore the role of diabetes. Having diabetes has been found to be a significant risk factor 159 
for colorectal cancer, yet can also be a significant barrier to screening attendance (Bell, 160 
Shelton & Paskett, 2001; McBean & Yu, 2007; Zhao et al., 2009; Porter et al., 2016) As 161 
evidence for this is currently not consistent (Porter et al 2016; Wilkinson & Culpetter, 2011) 162 
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we felt it was important to continue to test this association as it would have important 163 
implications for how diabetic patients prevent themselves from colorectal cancer.  164 
Being able to determine predictors of actual BSS attendance as part of a prospective 165 
design could provide novel insights into genuine barriers to BSS which could further enhance 166 
ongoing efforts to support individuals, particularly those who are inclined to have the test. 167 
This could further increase the potential of the programme to substantially reduce the public 168 
health burden associated with CRC incidence and mortality.  169 
 170 
Method 171 
Participants  172 
Between May 2015 and April 2016, 83 General Practices (GPs) located in England 173 
were recruited to this study. Questionnaires were sent to registered patients within each 174 
practice aged between 54 and 10 months and 55 and two months (the point at which they 175 
become eligible for BSS and receive their BSS pre invitation letter).  176 
GPs were asked to exclude patients who they did not consider to be proficient enough 177 
at reading English to understand and complete the questionnaire, and would not meet the 178 
eligibility criteria for BSS, i.e. patients who were diagnosed with CRC, ulcerative colitis, 179 
diverticular disease or Crohn’s disease.  180 
Ethical approval 181 
This study received ethical approval from NRES Committee South Central-Berkshire 182 
B (letter dated 21st May 2014). 183 
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Procedures and Materials   184 
Overall 4,330 eligible patients were assigned unique study IDs to keep the 185 
questionnaires anonymous and sent study invitation packs, which contained a GP cover letter, 186 
an 8-page questionnaire booklet, and a freepost return envelope addressed to the researchers. 187 
Docmail Ltd, a hybrid online mailing company, was employed for the printing, assembling 188 
and delivery of the study invitation packs. 189 
The GP cover letter contained a short explanation of the study and encouraged 190 
recipients to return the questionnaire, either completed or not, using the freepost return 191 
envelope. All participants were informed that by returning a completed questionnaire they 192 
were providing consent for their data to be used in this study. A reminder letter was sent at 193 
two (with new copy of questionnaire) and four (letter only) weeks to individuals who did not 194 
return a questionnaire. Such individuals were identified by each practice through elimination 195 
of study ID numbers on returned questionnaires. Completed questionnaires were returned for 196 
analysis between June 2015 and July 2016. In line with the stipulation by our funding body 197 
(see funding statement), we did not provide any incentive or compensation for questionnaire 198 
completion.   199 
Questionnaire 200 
Outcome variables. A participant’s intention to attend screening when invited was 201 
assessed during questionnaire completion with a single question: ‘Do you think you will take 202 
up the offer when invited to have the test (bowel scope screening)?’ with the following 203 
response options: ‘definitely not’, ‘probably not’, ‘yes probably’ and ‘yes definitely’  204 
Hypothesis 1 (H1). A recent retrospective study of BSS attendance demonstrated that 205 
initial interest in bowel scope screening was 95%  (von Wagner et al., 2018) so we 206 
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hypothesised that a majority of survey respondents would initially intend to take part in 207 
Bowel Scope Screening. 208 
While intention is often used as a proxy for behaviour, we were able to subsequently 209 
and objectively measure behaviour, i.e. screening attendance, for a number of participants... 210 
Screening attendance information was requested from the Bowel Cancer Screening System 211 
for participants who noted their permission for this on their returned questionnaire. In 212 
addition to permission, personal information i.e. full name, date of birth and postcode was 213 
also required from the participant to fulfil this task. Attendance was then dichotomised into 214 
‘yes’ and ‘no’. 215 
Core HBM variables.  Fifteen items derived from the existing literature (Champion, 216 
1984; Wolf et al., 2001; McCaffery.et al., 2001) were included in the survey. The items 217 
reflected attitudes towards CRC and screening and were influenced by constructs of the 218 
HBM: barriers/costs to screening (e.g.  ‘I think the test would be painful’); benefits of the 219 
screening test (e.g. ‘I think that the test would reduce my chances of getting bowel cancer’); 220 
perceived susceptibility to cancer (e.g. I am at risk of getting bowel cancer in the future); 221 
perceived severity of bowel cancer (i.e. bowel cancer has serious consequences). Each item 222 
had five response options: ‘strongly disagree’, ‘disagree’, ‘not sure’, ‘agree’, ‘strongly 223 
agree’.   224 
Using an iterated principle factor analysis with varimax rotation (accepting factor 225 
loadings of more than 0.300), we merged twelve of the fifteen items into three factors: 1) 226 
perceived benefits of the test (five items, Cronbach α=0.71; e.g., ‘test would be important’), 227 
2) perceived barriers (four items, Cronbach α=0.64; e.g., ‘test would be painful’) and 3) 228 
perceived susceptibility to bowel cancer (three items, Cronbach α=0.63; e.g., ‘I am at risk of 229 
getting bowel cancer’).  Perceived seriousness did not fall within the factor structure but was 230 
11 
 
 
measured by a single item (‘I believe that bowel cancer has serious consequences’). A mean 231 
score was calculated for each of the three multi-item factors and scores for all four factors 232 
were used as continuous variables for the regression analysis.  233 
Non-core HBM variables. We also measured two non-core HBM constructs that did 234 
not form part of the original Health Belief Model, namely ‘health motivation’, and ‘cues to 235 
action’ with single items. Both were treated as dichotomous variables for the analysis.  236 
Health motivation. This was measured with the question, ‘How interested are you in 237 
getting information about other, non-screening, ways in which you could reduce your risk of 238 
getting bowel cancer?’. Responses were given on a 4-point Likert scale: ‘not at all’, 239 
‘somewhat’, ‘moderately’, ‘very’.   240 
Cues to action. For a measure of external ‘cues to action’, we asked respondents to 241 
indicate if they knew somebody who has ever had bowel cancer with 6 options provided: 242 
partner, close friend, other friend, family member (blood relative), family member (non-blood 243 
relative) or unsure. Responses were divided into ‘Family history of bowel cancer’ (blood 244 
relatives vs no blood relatives or unsure) and ‘Friend/non-blood relative with history of 245 
bowel cancer’ (friends and non-blood relatives vs no friend/relative with history of bowel 246 
cancer or unsure) so as to distinguish cues as either a potential hereditary link to bowel cancer 247 
compared to knowledge of another’s personal experience.   248 
H2: In accordance with the HBM, we hypothesised that screening attendance would 249 
be predicted by higher perceived benefits, perceived susceptibility, perceived seriousness, 250 
and health motivation. In addition, knowing someone with the disease (‘cue to action’) would 251 
also be predictive of screening attendance. Conversely, we predicted that higher perceived 252 
barriers would be negatively associated with attendance.  253 
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Non-HBM variables. We added questions to measure theoretical constructs not 254 
linked to the HBM i.e. fatalism and knowledge.  255 
H3. We hypothesised that better knowledge of risk factors would be positively 256 
associated with bowel cancer screening attendance and that stronger fatalistic beliefs would 257 
be negatively associated with attendance. 258 
Fatalism. The items ‘Getting bowel cancer is like a death sentence’ and ‘There is 259 
nothing I can do to stop myself getting bowel cancer’ where both treated as representing 260 
different aspects of fatalistic beliefs about colorectal cancer. Responses for both items were 261 
provided on a 5 point scale from ‘Strongly disagree’ to ‘Strongly agree’. Each one was 262 
entered individually as a continuous variable for the analysis.   263 
H4: We hypothesised that higher scores on fatalism would be negatively associated 264 
with screening attendance.  265 
Knowledge of risk factors. We calculated a knowledge score using 13 identified risk 266 
factors for bowel cancer (e.g. being overweight, having a diet high in red and processed meat) 267 
(Haggar & Boushey, 2013; Peeters, Bazelier, Leufkens, de Vries, & De Bruin, 2015). Each 268 
item had three response options: increases the risk; makes no difference; decreases the risk. 269 
Individuals were given a point for every correct answer. Scores ranged from 0 to 13, with 270 
high scores indicating better knowledge of CRC risk factors.  271 
H5: We hypothesised that higher knowledge scores would be positively associated 272 
with Bowel Scope Screening attendance.  273 
Health and lifestyle variables 274 
Health behaviours. We assessed if individuals reporting eating at least 5 portions of 275 
fruit/vegetables per day (7 point scale; ‘Less than 1 per week’ to ‘3 or more per day’ for fruit 276 
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and vegetables separately) and how often they partake in at least 30 minutes of exercise of 277 
moderate activity (5 point scale; ‘Never/Cannot exercise’ to ‘Everyday). We additionally 278 
included a question on current smoking habits (never smoked; ex-smoker; smoker; reversed 279 
scored). Individuals were considered to be following recommendations if they indicated they 280 
ate 5 or more pieces of fruit/veg per day, exercised for a minimum of 30 minutes at least 5 281 
days a week, and were a non-smoker.  282 
H6: We hypothesised that those who followed all recommendations would be more 283 
likely to attend bowel cancer screening, in view that bowel cancer screening is a 284 
‘recommendation’ from the NHS.  285 
External/circumstantial variables. 286 
Sociodemographic items. This included gender (male; female), marital status (single; 287 
married; cohabiting/ living with partner; divorced/ separated; widowed), ethnicity (White 288 
British; other), and employment status (employed full-time; employed part-time; self-289 
employed; unemployed; full-time homemaker; retired; student; disabled or too ill to work). 290 
Age (in years) was requested as an open response.  291 
Individual-level socioeconomic status.  This was derived from three demographic 292 
questions on having a formal education and home and car ownership. Individuals were given 293 
a point if their household did not own a car or van, they had no formal qualifications and they 294 
did not own their own home. Scores, therefore, ranged from 0 to 3 with high scores indicating 295 
higher levels of social deprivation.  296 
Area-level measure of socioeconomic status. The Index of Multiple Deprivation 297 
(IMD), was derived from participants’ postcode in order to compare respondents and non-298 
respondents. The IMD is a classification that uses area-based items such as income, 299 
employment, health and disability, education, skills and training, barriers to housing and 300 
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services, crime and living environment (Department for Communities and Local 301 
Government, 2011). On the basis of previous evidence we hypothesised a negative 302 
association between attendance and individual level markers of deprivation.  303 
Health status. We assessed self-rated health status with the question ‘Would you say 304 
that for someone your age, your health in general is excellent; good; fair; or poor. We 305 
anticipated that those who reported excellent or good health would be less likely to attend 306 
screening in line with the commonly noted barrier to screening of not feeling it is personally 307 
needed (Palmer, Thomas, von Wagner, Raine, 2014). 308 
Co-morbidities.  We asked respondents to report if they had ever been diagnosed with 309 
irritable bowel syndrome (IBS) or diabetes. Conversely to feeling healthy, we hypothesised 310 
that being diagnosed with IBS would predict screening attendance as the condition is 311 
associated with colorectal cancer related symptoms. With regard to diabetes, we anticipated a 312 
negative relationship with attendance in line with previous research (Porter et al., 2019).  313 
We also asked respondents to indicate if they had had a diagnosis of colorectal cancer, 314 
ulcerative colitis, Crohn’s disease and diverticular disease so that we could exclude them 315 
from the analysis as they were likely to be receiving care that involves regular colonoscopies 316 
and therefore would not be eligible for bowel scope screening. 317 
 318 
Analysis 319 
We analysed intention and attendance data separately. Using responses to the 320 
intention question, we classified respondents as either ‘intenders’ (‘yes definitely’ or ‘yes 321 
probably’), or ‘non-intenders’ (‘probably not’ or ‘definitely not’). Owing to the high 322 
proportion of intenders among our sample, we focused exclusively on intenders in our 323 
prospective analysis of screening attendance. Intenders were further classified as ‘attendees’ 324 
15 
 
 
if they had agreed for their screening records to be checked and the records subsequently 325 
confirmed that they had successfully attended BSS. They were classified as ‘non-attenders’ if 326 
their records showed that they had not attended. See Figure 1 for a flow diagram of study 327 
participation. 328 
In the first set of analyses, we examined differences between non-intenders and 329 
intenders in a series of Chi-square tests for categorical and ANOVA for continuous variables 330 
respectively. Significant predictors were then included in an adjusted logistic regression. 331 
In the second set of analyses, we focused on identifying prospective predictors of 332 
attendance among intenders only. To this end, we again explored the data for differences 333 
between attenders and non-attenders using Chi-square for categorical and ANOVA for 334 
continuous variables respectively. We then conducted unadjusted logistic regressions 335 
followed by adjusted regression containing significant predictors (at p <=0.05) at the 336 
univariate level. All statistical analysis was conducted with Stata/SE version 15.1 (StataCorp 337 
LP, College Station, TX). 338 
Results 339 
The questionnaire was sent to 4,330 eligible individuals with 1,688 (39.0%) returning 340 
a questionnaire that was at least partially completed. Questionnaire respondents were more 341 
likely to be female than male (41.4% vs 36.6%, x2 (1, N=4,329) = 10.83, p=0.001). Those 342 
who completed and returned a questionnaire were more likely to live in an area with low 343 
deprivation (i.e. in the first quintile 27.8% vs 17.4%, x2 (4, N=4,024) = 128.58, p<0.001). 344 
Among those who returned a completed questionnaire, 110 (6.5%) were removed 345 
from the analysis due to the reported age being outside the study eligibility (i.e. below 54 or 346 
above 56) or a diagnosis of  Ulcerative colitis, Diverticular disease, Crohn’s disease or bowel 347 
cancer was noted, rendering the individual ineligible for screening. Of the questionnaire 348 
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respondents included in the final analysis (N=1,578), the majority were female (53.4%), 349 
married or cohabiting (88.4%), white (92.1%) and were living in the least deprived quintile of 350 
deprivation (28.0%).  351 
Non-intenders vs intenders 352 
Among the 1,555 (98.5%) respondents for whom intention was recorded, 1,415 353 
(91.0%) were classified as intenders and 140 (9.0%) as non-intenders. Tables 2a and 2b show 354 
a comparison of non-intenders and intenders. Mean and standard deviations are displayed for 355 
continuous attitude items. Variables such as ethnicity, working status and health status were 356 
dichotomised due to low frequencies.  357 
Variables that were statistically significant in unadjusted logistic regressions were 358 
carried forward into in an adjusted model (see Table 3). Intention to do the screening test was 359 
positively associated with scoring higher on a scale of perceived benefits (OR: 4.62; 95% CI: 360 
3.24-6.58) and health motivation, (OR: 2.61.; 95% CI: 1.62-4.22). Conversely, scoring higher 361 
on a scale of perceived test barriers (OR: 0.19: 95% CI: 0.12-0.31) and following 362 
recommendations for a healthy lifestyle (OR: 0.31; 95% CI: 0.16-0.59) were negatively 363 
associated with intention. 364 
Verification of attendance  365 
1,342 (85.0%) participants gave permission for researchers to access their screening 366 
records (using their first and last name, date of birth and postcode) via the NHS Bowel 367 
Cancer Screening system: 236 (15.0%) explicitly declined. There were no sociodemographic 368 
differences in terms of ethnicity, gender, deprivation or working status between those who 369 
did and did not give permission.  922 (72.3%) of those who intended and gave permission 370 
could successfully be matched to screening records (screening records were examined in 371 
March 2017, 8-21 months post questionnaire completion). There were no relevant statistically 372 
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significant sociodemographic or intentional differences between those who could be matched 373 
or those who could not.  374 
Predictors of attendance among intenders 375 
Of the 922 intenders with verified attendance, 737 (79.9%) successfully completed 376 
BSS screening while 185 (20.1%) did not. Tables 4a and 4b show the differences between 377 
non-attenders and attenders among intenders. A multivariate analysis of the variables with 378 
significant between group differences (see table 5) confirmed that with regard to core HBM 379 
variables, scoring lower on a scale of perceived barriers (OR: 0.47; 95%CI: 0.32-0.69) and 380 
higher on perceived benefits of the test (OR: 1.82; 95% CI: 1.37-2.43) predicted attendance, 381 
as did having high motivation to find out about other non-screening CRC prevention methods 382 
(OR: 1.75; 95% CI: 1.07-2.86). This was independent of other predictors including being in 383 
the least deprived category of individual deprivation and reporting diabetes. 384 
Discussion 385 
This prospective survey of predictors of attendance at bowel scope (flexible 386 
sigmoidoscopy) screening highlights the value of several HBM variables. While our analysis 387 
of intention was limited by the large majority of respondents intending to have the test, it was 388 
noteworthy that the pattern of results was similar for intention and action. Two core 389 
constructs of the HBM, perceived benefits and perceived barriers of the test, emerged as 390 
important predictors for not only intention but additionally for action within intenders, 391 
suggesting that the reduction of perceived barriers and continued communication of the 392 
benefits are needed throughout the screening invitation and appointment process. From 393 
previous retrospective work we know that the specific barriers to screening differ for those 394 
classified as non-responders to the screening invitation, decliners of the invitation and those 395 
who intend to go but then do not attend: from emotive to more practical barriers (von Wagner 396 
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et al, 2019). However, the benefits of being screened are likely more consistent across the 397 
invitation process. Even within intenders there is room to further promote benefits of 398 
screening to ensure action/attendance is likely.   399 
For the other two core HBM variables, perceived susceptibility and seriousness, a 400 
different story emerged. Perceived seriousness was not a predictor for either intention or of 401 
subsequent action, perhaps highlighting that the seriousness of CRC is an accepted position 402 
for the general public. While a significant difference in ‘Perceived susceptibility’ was found 403 
between intenders and non-intenders (low susceptibility) this disappeared in the adjusted 404 
model, suggesting that a heightened perceived personal risk of CRC is already accounted for 405 
within another variable, possibly perceived benefits (e.g. feeling the test would reduce 406 
chances of getting bowel cancer). Following this, perceived susceptibility was also not a 407 
predictor of action.  408 
Health motivation is a less well studied aspect of the HBM, but was found to be 409 
influential to both screening intentions and behaviour. In this study, interest in finding out 410 
more about non-screening ways to prevent CRC was strongly associated with BSS 411 
attendance, perhaps suggesting that promoting this specific test should become part of a 412 
wider conversation about CRC prevention, and more specifically improving bowel health. 413 
This would be as a supplement to encouraging general healthy lifestyle choices such as non-414 
smoking, eating 5 pieces of fruit and vegetables a day, and exercising for at least 30mins for a 415 
minimum of 5 days a week. Not following such lifestyle recommendations was found to be a 416 
predictor of intention only. As motivation to know more about preventing CRC continued to 417 
be a predictor of attendance, more specific education for CRC prevention may be required. 418 
Of particular interest is the importance of individual-level deprivation and a diagnosis 419 
of diabetes in bridging the gap between intention and attendance at screening. Individual-420 
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level deprivation was negatively associated with both intention and attendance and while it 421 
was explained by another variable included in our final multivariate models for intention, it 422 
was found to be an independent predictor of attendance. This finding maps on to 423 
epidemiological studies looking at uptake of BSS (McGregor et al., 2016).  However,  much 424 
less is known about why deprivation is associated with either material or psychological 425 
barriers. Our own research has identified that at least some of this relationship can be 426 
explained by differences in time perspective and the willingness or ability to ensure short-427 
term costs associated with having the test in return of longer-term gains (Whitaker et al, 428 
2011). This is particularly relevant as bowel scope screening is associated with a number of 429 
so-called opportunity costs or indirect costs such having to take time off work, travel to the 430 
clinic, having to prepare the bowel and the discomfort associated with the procedure.    431 
Furthermore, the results support recent interest in people with co-morbidities. Our 432 
finding on the role of diabetes as a barrier to attendance was in support of earlier research 433 
(e.g. Bell, Shelton & Paskett, 2001) but at odds with current evidence from North America 434 
which found that people with diabetes are more likely to undergo colorectal cancer screening 435 
and that the relationship is likely to be moderated by how well patients can control their 436 
diabetes (Porter et al 2016; Wilkinson & Culpetter, 2011).  As such, it is important to better 437 
understand the exact role living with diabetes plays.  For example, our finding highlights that 438 
one should review bowel cancer risk awareness among diabetic patients and the extent to 439 
which there are specific barriers that might prevent informed decision making in this group.      440 
In contrast to findings reported in a highly cited paper on the intention-behaviour gap 441 
in the UK FS trial by Power and colleagues (Power et al., 2008), we found that attendance 442 
was predicted by a combination of motivational barriers rather than more upstream and less 443 
modifiable barriers such as socioeconomic / area deprivation, and poor health status. Our 444 
findings suggest that in this programme even those who intend to do the test would therefore 445 
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benefit from more education about the benefits of the test and how to overcome anticipated 446 
barriers.  447 
The finding that following recommendations for healthy behaviours is negatively 448 
associated with intention to be screened was counterintuitive as one would expect people 449 
with a healthy lifestyle to be more health conscious. However, qualitative literature on 450 
reasons for non-attendance has highlighted that people who lead healthy lifestyles often use 451 
this as a reason why they do not need to go for cancer screening (McCaffery et al 2001). Our 452 
finding suggests that more needs to be done to communicate that screening is for the entire 453 
screening-eligible population, regardless of health status and lifestyle. In addition, there is an 454 
urgent need to address modifiable barriers. However, it is also important to note that future 455 
research should try and identify predictors of attendance in the entire screening eligible 456 
population to capture the difference between other sub-groups such as disinclined attenders 457 
and disinclined non-attenders.  458 
Barriers were grouped together for our analysis, but included perceived 459 
embarrassment and pain. Embarrassment, for example, could be addressed by making same-460 
sex practitioners more widely available. Anticipated pain could be addressed by emphasising 461 
the option to use Entonox, a pain relief gas, during the procedure. 462 
While it is important to emphasise that FS screening is offered for free in England, 463 
and employs an organised and population-based process of invitation so theoretically 464 
everyone in our sample had equal opportunities to attend, participation still involves indirect 465 
costs such as preparation, travel and waiting time.  466 
The fact that we could not fully explain uptake with our variables suggests that other 467 
factors may be at play (29% and 11% of the variance was explained for intentions and 468 
attendance respectively). Previous evidence has suggested consideration of future 469 
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consequences (CFC) and fatalism (von Wagner, Good, Smith, & Wardle, 2012; Whitaker, 470 
Good, Miles, Robb, Wardle & von Wagner 2011). In our study, we did not find fatalistic 471 
beliefs to be significant independent predictors of attendance. To better understand the role of 472 
SES, alternative measures, specifically geospatial and consumer information could add 473 
important insights and provide richer data about contextual determinants of screening uptake. 474 
As with diabetes, low SES in itself is associated with an increased risk of developing and 475 
dying from bowel cancer (Doubeni et al., 2012) and so deserves further attention when trying 476 
to optimise BSS delivery and uptake. 477 
Our study had several limitations. Despite the use of two reminders, response to the 478 
questionnaire was 39%, which introduced an important selection bias, evident in the 479 
proportion of intenders and attenders and low overall SES distribution and lack of ethnic 480 
diversity in our sample. As a result our research may have left out some of those at risk of 481 
failing to attend screening. This limits our ability to make definitive conclusions about the 482 
relative importance of our predictors, and perhaps more importantly means that variables 483 
which are associated with BSS attendance did not emerge in our analysis. In our effort to 484 
make the questionnaire acceptable we were also unable to include all potential predictors of 485 
uptake and to explore their role as potential mediators of socio-demographic patterns 486 
observed in FS screening. While we obtained consent from 85% of participants to access 487 
personal screening records, we could only verify and match with intention, 73% of them. The 488 
remaining 27% either provided inaccurate or ineligible details on full name, date of birth and 489 
postcode (which were required to match their NHS records). Furthermore, there was no 490 
adequate measure capturing potential attitudes towards FS screening that would have 491 
adequately captured the organisation and context of the new BSS programme. While we 492 
conducted a factor analysis, we did not have the ability to test the reliability of the structure 493 
by testing it on another sample. Finally, our analytical approach focused on identifying direct 494 
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associations between each possible explanatory and outcome variables. This approach did not 495 
account for the relationships between exploratory variables and the indirect effects of 496 
variables. Future research using mediation analysis could identify indirect links. 497 
Notwithstanding its limitations, this study also had many important strengths. Most 498 
importantly, the fact that we were able to capture prospective predictors rather than 499 
retrospective correlates of uptake. The benefits of this have been well documented in the 500 
literature (Vandenbroucke, 2008) and this study adds important weight to raising awareness 501 
of the importance of perceived barriers, which can often be difficult to interpret in the context 502 
of non-attenders retrospectively reflecting on the reasons why they did not take up the 503 
invitation for screening (Waller, Bartoszek, Marlow & Wardle, 2009). Another strength was 504 
our ability to verify uptake rather than relying on self-report. 505 
This prospective study provided contrasting findings from the UK FSST, by finding 506 
attendance to be predicted by a range of attitudinal and psychosocial factors including 507 
perceived importance and test-specific barriers. This suggests more needs to be done to 508 
educate the public about the value of the test, and where possible reduce anticipated barriers 509 
such as embarrassment. 510 
  511 
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Table 1 Classification of the attitudinal variables 
Original variable/question Variable / Construct Cronbach α 
Core HBM variables    
I think the test would be important to do 
Perceived benefits 0.71 
I think the test would give me peace of mind 
I think the test would reduce my chances of 
getting bowel cancer 
I think the test would reduce my chances of 
dying from bowel cancer 
I think the test would be painful 
Perceived barriers 0.64 
I think the test would take too much time 
I think the test would be embarrassing 
I think the test would be unnecessary if I did not 
have any symptoms 
I think the enema would be off-putting 
I am at risk of getting bowel cancer in the future 
Perceived susceptibility 0.63 
I am more likely than the average person of my 
age and gender to get bowel cancer 
I am worried about getting bowel cancer 
I believe that bowel cancer has serious 
consequences 
Perceived severity 
- 
Non-Core HBM   
Have any of the following people ever had bowel 
cancer (blood and non-blood relatives and 
friends) 
Cues to action  
 
How interested are you in getting information 
about other ways (not screening) of reducing 
your chance of getting bowel cancer? 
Health motivation  
 
Non-HBM beliefs   
Getting bowel cancer is like a death sentence Fatalism (death) - 
There is nothing I can do to stop myself  getting 
bowel cancer 
Fatalism (control) 
- 
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Table 2a Difference in knowledge, attitudes and beliefs among non-intenders and 
intenders (univariate analysis) † 
  Non-intenders 
(N=140) 
Intenders  
(N=1,415) p-value* 
  Mean (SD) Mean (SD) 
Core HBM variables      
 Perceived benefit  2.43 (0.67) 3.03 (0.62) <0.001 
 Perceived barriers  2.11 (0.52) 1.82 (0.49) <0.001 
 Perceived susceptibility 1.90 (0.66) 2.13 (0.68) 0.001 
 Perceived seriousness 3.32 (0.99) 3.44 (0.86) 0.146 
Non HBM variables      
 Fatalistic belief (death) 1.82 (1.05) 1.92 (1.04) 0.290 
 Fatalistic belief (control) 1.22 (0.93) 1.20 (0.88) 0.796 
 Knowledge of risk factors 9.62 (2.42) 9.61 (2.22) 0.971 
*The p-values are derived from ANOVA  
† Only eligible sample (i.e. without bowel cancer, ulcerative colitis, diverticular disease or 
Crohn’s disease for whom screening status could be verified).  
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Table 2b Difference among non-intenders and intenders (univariate analysis) † 
  Non-intenders 
(N=140) 
Intenders 
(N=1,415) p-value* 
  N (%) N (%) 
Non-Core HBM constructs      
Cues to action      
 Family history of bowel cancer      
  No/unsure 124 (9.78%) 1144 (90.22%) 
0.025 
  Yes 16 (5.57%) 271 (94.43%) 
 Friend/non-blood relative with bowel cancer     
  No/unsure 110 (9.47%) 1052 (90.53%) 
0.272 
  Yes 30 (7.63%) 363 (92.37%) 
Health motivation      
 Interest in non-screening prevention methods    
  Not at all/somewhat 49 (21.59%) 178 (78.41%) 
<0.001 
  Moderately/very 87 (6.61%) 1229 (93.39%) 
Health and lifestyle variables      
 Health behaviours      
  Not following recommendations 115 (13.00%) 1312 (91.94%) 
<0.001 
  Following recommendations 22 (20.37%) 86 (79.63%) 
External/circumstantial variables    
Sociodemographic details      
 Self-stated age      
  54 years 113 (9.33%) 1098 (90.67%) 
0.397 
  55 years 27 (7.85%) 317 (92.15%) 
 Gender      
  Male 63 (8.68%) 663 (91.32%) 
0.675 
  Female 77 (9.29%) 752 (90.71%) 
 Living condition      
  Married/cohabiting 116 (8.45%) 1257 (91.55%) 
0.031 
  Single/divorced/widowed 24 (13.33%) 156 (86.67%) 
 Ethnicity      
  White 131 (9.21%) 1292 (90.79%) 
0.468 
  Other 9 (7.26%) 115 (92.74%) 
 Paid work      
  No 31 (13.54%) 198 (86.46%) 
0.007 
  Yes 105 (8.02%) 1204 (91.98%) 
Area level deprivation (IMD quintiles)     
  Least deprived 33 (8.07%) 376 (91.93%) 
0.089 
  2nd 29 (7.99%) 334 (92.01%) 
  3rd  21 (7.32%) 266 (92.68%) 
  4th  22 (9.78%) 203 (90.22%) 
  Most deprived 25 (14.29%) 150 (85.71%) 
Individual deprivation markers      
  0 (least deprived) 98 (8.51%) 1054 (91.49%) 
<0.001   1  19 (7.17%) 246 (92.83%) 
  2-3  21 (20.19%) 83 (79.81%) 
Health status      
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  Poor/fair 43 (10.26%) 376 (89.74%) 
0.279 
  Good/excellent 95 (8.49%) 1024 (91.51%) 
Comorbidities      
 Irritable bowel syndrome      
  No 119 (8.85%) 1225 (91.15%) 
0.604 
  Yes 21 (9.95%) 190 (90.05%) 
 Diabetes      
  No 131 (8.91%) 1339 (91.09%) 
0.600 
  Yes 9 (10.59%) 76 (89.41%) 
† Only eligible sample (i.e. without bowel cancer, ulcerative colitis, diverticular disease or 
Crohn’s disease).  
*The p-values are derived from Chi-square tests of independence  
Note that missing cases are not reported, so that the column frequencies do not always 
sum up to the total stated at the top of the table.
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Table 3 Unadjusted and adjusted logistic regression on intending to do the test 
 Unadjusted models Adjusted model 
 Odds 
ratio 
CI Odds 
ratio 
CI 
Core HBM constructs     
    Perceived benefits 3.687 2.783 - 4.886** 4.615 3.237 - 6.581** 
    Perceived barriers  0.282 0.191 - 0.417** 0.194 0.121 - 0.312** 
    Perceived susceptibility 1.694 1.297 - 2.213** 1.352 0.954 - 1.917 
Non-core HBM variables    
Cues to action     
    Family history of bowel cancer    
        No Ref.  Ref.  
        Yes 1.836 1.073 – 3.142* 1.187 0.615 – 2.291 
Health motivation     
    Interest in non-screening   
    prevention  methods 
   
        Not at all/somewhat Ref.  Ref.  
        Moderately/very 3.889 2.649 - 5.708** 2.612 1.617 - 4.220** 
Health and lifestyle variables    
Health Behaviours     
    Not following    
    recommendations 
Ref.  Ref.  
    Following   
    recommendations 
0.343 0.207 - 0.568** 0.311 0.164 - 0.590** 
External/circumstantial variables    
Sociodemographic variables     
    Living condition     
        Married/cohabiting Ref.  Ref.  
        Alone 0.600 0.375 - 0.960* 0.732 0.379 - 1.414 
    Paid work     
        No Ref.  Ref.  
        Yes 1.795 1.170 - 2.754** 1.316 0.724 - 2.395 
Individual Deprivation     
    0 markers (least deprived) Ref.  Ref.  
    1 marker 1.204 0.723 - 2.006 1.344 0.702 - 2.575 
    2-3 markers 0.367 0.218 - 0.619** 0.527 0.241 - 1.153 
N   1,421  
R2   0.290  
Left hand side of the table shows the unadjusted logistic regressions for those covariates who 
had a significant association with attendance. The right hand side shows the adjusted model 
for these variables.* p<0.05; ** p<0.01 
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Table 4a. Differences between non-attenders and attenders among intenders (univariate 
analysis)† 
  Non-Attenders 
(N=185) 
Attenders 
(N=737) p-value* 
  Mean (SD) Mean (SD) 
Core HBM variables      
 Perceived benefit  2.88 (0.63) 3.08 (0.61) <0.001 
 Perceived barriers  1.93 (0.49) 1.78 (0.48) <0.001 
 Perceived susceptibility 2.06 (0.68) 2.14 (0.65) 0.136 
 Perceived seriousness 3.38 (0.88) 3.46 (0.86) 0.276 
Non HBM variables       
 Fatalistic beliefs (death) 1.97 (1.04) 1.88 (1.05) 0.262 
 Fatalistic beliefs (control) 1.29 (0.88) 1.16 (0.89) 0.084 
 Knowledge of risk factors 9.58 (2.44) 9.73 (2.13) 0.419 
*The p-values are derived from ANOVA  
† Only eligible sample (i.e. without bowel cancer, ulcerative colitis, diverticular disease or 
Crohn’s disease for whom screening status could be verified).  
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Table 4b. Differences between non-attenders and attenders among intenders (univariate 
analysis)† 
  Non-Attenders 
(N=185) 
Attenders  
(N=737) p-value 
  N (%) N (%) 
Non-core HBM variables      
Cues to action      
 Family history of bowel cancer      
  No 157 (20.91%) 594 (79.09%) 
0.182 
  Yes 28 (16.37%) 143 (83.63%) 
 Friend/non-blood relative 
history of bowel cancer 
   
 
 
  No 149 (21.56%) 542 (78.44%) 
0.050 
  Yes 36 (15.58%) 195 (84.42%) 
Health motivation      
 Interest in non-screening 
prevention methods 
   
 
 
  Not at all/somewhat 32 (31.37%) 70 (68.63%) 
0.003 
  Moderately/very 153 (18.73%) 664 (81.27%) 
Health and Lifestyle Variables      
Health behaviours      
  Not following 
recommendations 171 
(13.00%) 
684 (80.00%) 0.947 
  Following recommendations 11 (20.37%) 43 (79.63%) 
External / circumstantial variables     
Sociodemographic details      
 Self-stated age      
  54 years 142 (19.75%) 577 (80.25%) 
0.653 
  55 years 43 (21.18%) 160 (78.82%) 
 Gender      
  Male 85 (20.29%) 334 (79.71%) 
0.878 
  Female 100 (19.88%) 403 (80.12%) 
 Living condition      
  Married/cohabiting 160 (19.37%) 666 (80.63%) 
0.110 
  Single/divorced/widowed 25 (26.32%) 70 (73.68%) 
 Ethnicity      
  White 169 (19.81%) 684 (80.19%) 
0.526 
  Other 15 (23.08%) 50 (76.92%) 
 Paid work      
  No 32 (24.24%) 100 (75.76%) 
0.183 
  Yes 151 (19.24%) 634 (80.76%) 
Individual deprivation      
  0 markers (least deprived) 122 (17.35%) 581 (82.65%) 
<0.001   1 marker 36 (23.23%) 119 (76.77%) 
  2-3 markers 21 (44.68%) 26 (55.32%) 
Area level deprivation (IMD 
quintiles)     
 
  Least deprived 40 (16.88%) 197 (83.12%) 0.158 
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  2nd 46 (20.26%) 181 (79.74%) 
  3rd  29 (17.16%) 140 (82.84%) 
  4th  29 (20.86%) 110 (79.14%) 
  Most deprived 27 (28.42%) 68 (71.58%) 
Health status      
  Poor/fair 59 (24.08%) 186 (75.92%) 
0.068 
  Good/excellent 125 (18.63%) 546 (81.37%) 
Comorbidities      
 Irritable bowel syndrome      
  No 162 (20.25%) 638 (79.75%) 
0.720 
  Yes 23 (18.85%) 99 (81.15%) 
 Diabetes      
  No 168 (19.24%) 705 (80.76%) 
0.009 
  Yes 17 (34.69%) 32 (65.31%) 
† Only eligible sample (i.e. without bowel cancer, ulcerative colitis, diverticular disease or 
Crohn’s disease for whom screening status could be verified).  
*The p-values are derived from Chi-square tests of independence  
Note that missing cases are not reported, so that the column frequencies do not always 
sum up to the total stated at the top of the table. 
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Table 5 Unadjusted and adjusted logistic regression models of attendance for intenders 
 Unadjusted model Adjusted model 
Variable Odds 
ratio 
95% CI Odds 
ratio 
95% CI 
Core HBM variables    
 Perceived benefits 1.65 1.276 - 2.146** 1.822 1.368 - 2.425** 
 Perceived barriers  0.521 0.368 - 0.739** 0.468 0.319 - 0.687** 
Non-core HBM variables     
Cues to action     
    Friend/non-blood relative history of   
    bowel cancer 
 
 
 
        No Ref.  Ref.  
        Yes 1.489 0.999 - 2.219 1.454 0.946 - 2.233 
Health motivation     
    Interest in non-screening prevention  
    methods 
 
 
 
         Not at all, somewhat Ref.  Ref.  
         Moderately, very 1.984 1.260 - 3.123** 1.749 1.071 - 2.858* 
External / circumstantial variables    
Individual deprivation    
     0 markers (least deprived) Ref.  Ref.  
     1 marker 0.694 0.456 - 1.057   0.775 0.496 - 1.211 
     2-3 markers 0.260 0.142 - 0.477** 0.258 0.135 - 0.495** 
Diabetes     
    No Ref.  Ref.  
    Yes 0.49 0.243 - 0.827* 0.479 0.245 - 0.938* 
N   884  
R2   0.107  
Left hand side of the table shows the unadjusted logistic regressions for those covariates who 
had a significant association with attendance. The right hand side shows the adjusted model 
for these variables. 
* p<0.05; ** p<0.01 
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Figure 1 Flow through the study 
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